Improved Breast Cancer Therapy (I-BCT-1) in the Neoadjuvant and Metastatic Setting
Status:
Active, not recruiting
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
The purpose of the study is to investigate the molecular biology of the tumor in relation to
treatment response to chemotherapy, in particular paclitaxel compared to the combination
paclitaxel and carboplatin. The study is carried out in two different, separate cohorts:
Cohort I: Patients with large primary breast cancer (> 2.0 cm) including locally advanced
disease, are treated with weekly paclitaxel for 12 weeks, before continuing on anthracycline
containing regimen for another 12 weeks before surgery. Patient are randomized 1:1 to receive
carboplatin in addition to paclitaxel for the first 12 weeks of the treatment.
Cohort II: Patients with metastatic disease, available for biopsies before and during therapy
are included to receive paclitaxel for 24 weeks. Patients are randomized 1:1 to receive
paclitaxel alone or paclitaxel in combination with carboplatin.